Quick Answer
NEPHROS INC reported R&D Expense of $1.34 million for fiscal year 2025.
NEPHROS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.34M | +47.8% |
| 2024 | $906.0K | +3.8% |
| 2023 | $873.0K | -30.4% |
| 2022 | $1.25M | -16.2% |
| 2021 | $1.50M | -45.7% |
| 2020 | $2.76M | -10.7% |
| 2019 | $3.09M | +100.8% |
| 2018 | $1.54M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $338.0K | +79.8% | +8.7% |
| June 30, 2025 | $311.0K | +22.4% | +5.4% |
| March 31, 2025 | $295.0K | +39.2% | +56.9% |
| September 30, 2024 | $188.0K | -8.3% | -26.0% |
| June 30, 2024 | $254.0K | +14.9% | +19.8% |
| March 31, 2024 | $212.0K | -11.3% | +3.4% |
| September 30, 2023 | $205.0K | -18.7% | -7.2% |
| June 30, 2023 | $221.0K | -19.0% | -7.5% |
- NEPHROS INC showed an increase of +47.8% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, NEPHROS INC’s r&d expense has declined by 13.0% (from $1.54 million to $1.34 million).
- The most recent figure is from NEPHROS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: